Please login to the form below
enasidenib
This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.
Novartis gets EU nod for leukaemia drug Rydapt
or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.
Latest news
-
Celgene, Agios get FDA OK for leukaemia drug Idhifa
Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer
-
Celgene bags US priority review for cancer metabolism drug
First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
-
Account Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Associate Director
-
£75, 000-90, 000
-
Senior Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Medical Writer
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Account Director, Medical Education
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
OUTiCO
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
